Blog
Get the latest news about liver diseases and more
Get the latest news about liver diseases and more
Hepatitis C has become the real protagonist of Spanish health for a few months, as a result of the protests initiated by patients (with enclosures in hospitals included).
We participated in the conversation Hepatitis C: Challenge for health, promoted by Fuinsa and Servimedia and that took place in the Press Association of Madrid.
TG4040 is a modified Ankara vaccine virus that expresses the hepatitis C virus NS3, NS4 and NS5B proteins (therapeutic vaccine). The Foundation participated in a phase II clinical trial in patients with chronic hepatitis C.
Between November 1-5, 2013, the 64th Annual Congress of the American Association for the Study of Liver Disease was held in Washington (USA)
En agosto la revista New England Journal of Medicine publica un artículo sobre el tratamiento libre de interferón de la hepatitis crónica C con Faldaprevir (inhibidor de la proteasa del virus) y Deleobuvir (inhibidor de la polimerasa vírica).
A new study by members of the Foundation for the Study of Viral Hepatitis on the presence of hidden hepatitis C in patients with chronic hepatitis B is published in the Journal of Medical Microbiology.
In January of this year two important studies of Hepatitis C treatment without interferon have been published. So Kowdley et al (NEJMed, 222-232) have used three inhibitory drugs from different areas of the C virus.
Currently there are antiviral treatments against chronic hepatitis C (pegylated interferon + ribavirin + inhibitors) with a favorable response in 75% of cases. However, these treatments can have important side effects and contraindications for its administration.
15 de February de 2020
19 de March de 2022
13 de January de 2024